Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Ayu KiritaniYoshiaki AminoKen UchiboriTakahiro AkitaYuhei HarutaniShinsuke OgusuRyosuke TsugitomiRyo ManabeRyo AriyasuSatoru KitazonoNoriko YanagitaniMakoto NishioPublished in: Thoracic cancer (2024)
Among patients with EGFR-mutation positive NSCLC, the evidence of MPE has little effect on survival with osimertinib.